Neoadjuvant chemoradiation for XXXX is not associated with higher rates of @entity1031 .

@entity5 @entity1 @entity204 @entity1031
AIM: @entity1031 ( @entity1031 ) is a leading cause of @entity204 amongst @entity5 @entity1 . The effect of neoadjuvant chemoradiotherapy (nCRT) on the risk of @entity1031 in @entity5 @entity1 is unknown. The aim of this study was to determine whether nCRT was associated with an increased risk of @entity1031 in @entity1 with @entity5 , either during therapy or with subsequent treatment. METHOD: This was a retrospective study from a prospectively maintained database at a tertiary referral centre. @entity1 included @entity1 with @entity5 treated between January 2000 and December 2013. The primary outcome was the rate of @entity1031 in @entity1 with @entity5 who had nCRT compared with those who did not. RESULTS: One hundred and seventy-one (7.8%) of 2181 @entity5 @entity1 developed @entity1031 . @entity1 who had nCRT did not have an increased incidence of @entity1031 compared with those who had surgery alone (81/946, 8.6% vs 94/1235, 7.6%, P = 0.42) after a median follow-up of 95 months. Ten (1.1%) of 946 @entity1 who received nCRT developed @entity1031 during or immediately after nCRT. Most @entity1031 events occurred in the 30-day postoperative period (70 @entity1 , 3.2%). CONCLUSION: The prevalence of @entity1031 in @entity1 with @entity5 was 7.8%, with most events occurring in within 30 days of surgery. Neoadjuvant chemoradiation was not associated with an increased risk of @entity1031 .
